Objective To explore the standardized performance of a FISH probe before clinical detection.Methods The probe sensitivity and specificity of ETV6/RUNX1 were analyzed via interphase and metaphase FISH in 20 discarded healthy bone marrow samples.The threshold system of the probe was established using an inverse beta distribution,and an interpretation standard was established.Finally,a parallel-controlled polymerase chain reaction detection study was conducted on 286 bone marrow samples from patients at our hospital.The clinical sensitivity,specificity,and diagnostic coincidence rate of ETV6/RUNX1 FISH detection were analyzed,and the diagnostic consistency of the two methods was analyzed by the kappa test.Results The probe sensitivity and specificity of the ETV6/RUNX1 probe were 98.47％and 100％,respectively.When 50,100,and 200 cells were counted,the typical positive signal pattern cutoffs were 5.81％,2.95％,and 1.49％,respectively,and the atypical positive signal pattern cutoffs were 13.98％,9.75％,and 6.26％,respectively.The clinical sensitivity of FISH was 96.1％,clinical specificity was 99.6％,diagnostic coincidence rate was 99.00％,diagnostic consistency test kappa value was 0.964,and P value was＜0.001.Conclusion For FISH probes without a national medical device registration certificate,standardized performance verification and methodology performance verification can be performed using laboratory developed test verification standards to ensure a reliable and accurate reference basis for clinical diagnosis and treatment.
fluorescence in situ hybridizationSensitivitySpecificityThe diagnostic coinci-dence rateLaboratory developed test
维普
万方数据
